Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

We aimed to characterise where in the brain and when in the course of the disease neuroimaging biomarkers become abnormal. Findings suggesting differential regional and temporal vulnerabilities to Aβ, metabolic decline, and structural atrophy, which should be taken into account when using biomarkers in a clinical setting as well as designing and evaluating clinical trials.

More information Original publication

DOI

10.1016/S1474-4422(18)30028-0

Type

Journal article

Publisher

The Lancet Neurology

Publication Date

03/2018

Volume

17